±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 1509  |  »Ø¸´: 8
µ±Ç°Ö÷ÌâÒѾ­´æµµ¡£
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

yyzone

½ð³æ (³õÈëÎÄ̳)

[½»Á÷] ·½·¨Ñ§ÑéÖ¤ÖйØÓÚ»ØÊÕµÄÎÊÌâ

ÇëÎÊ´ó¼ÒÔÚ×ö·½·¨Ñ§ÑéÖ¤»ØÊÕʱ£¬ÔõôÅäÖÆÑùÆ·£¿

±ÈÈçÎÒÏë×öµÍ£¬ÖУ¬¸ßŨ¶ÈΪ80%£¬100%£¬120%µÄ»ØÊÕ£¬
ÔÚÅäÖÆÊ±  
1. ÊÇÅäÖÆµÍ£¬ÖУ¬¸ßŨ¶È¸÷3·ÝÑùÆ·£¬Ã¿·ÝÑùÆ·¸÷½øÑù1Õë¡£
2. »¹Êǵͣ¬ÖУ¬¸ßŨ¶È¸÷ÅäÖÆ1·Ý£¬Ã¿¸öŨ¶ÈµÄ¸÷½øÑù3Õë¡£

´ó¼ÒÓÐʲôÅжϵÄÒÀ¾Ý£¿·ÇCPµÄ£¬ÀýÈçUSP»òICHÉϵÄ
»Ø¸´´ËÂ¥
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

chenfengpolang

½ð³æ (ÖøÃûдÊÖ)

¡ï
karl2100(½ð±Ò+1,VIP+0):ллָµã£¡
ÊÇÅäÖÆµÍ£¬ÖУ¬¸ßŨ¶È¸÷3·ÝÑùÆ·£¬Ã¿·ÝÑùÆ·¸÷½øÑù2Õë¡£
²»ÊǽøÒ»Õ룬Óë²âº¬Á¿Ò»Ñù¡£
³Ë·çÆÆÀË£¬ÉúÉú²»Ï¢£¬ÏÎÒ»Ö¦éÏé­£¬ÎªÄã´øÀ´ÓÀÔ¶µÄ´ºÌ죬ºÍÄãÂýÂýµØ±äÀÏ£¬ÐÒÔÕ£¬ÀÖÔÕ£¡
3Â¥2008-09-05 20:10:53
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 9 ¸ö»Ø´ð

poeyoung

Í­³æ (СÓÐÃûÆø)

¡ï
karl2100(½ð±Ò+1,VIP+0):3Q
FDA µÄ
Reviewer Guidance
Validation of
Chromatographic Methods
ÔÚ½²×¼È·ÐÔÄǽÚÕâÃ´ÍÆ¼öµÄ£º
Recommendations:
Recovery data, at least in triplicate, at each level (80, 100 and 120% of
label claim) is recommended. The mean is an estimate of accuracy and
the RSD is an estimate of sample analysis precision.

ÎÒÃÇÆ½Ê±×öµÄʱºòÊǾ«Ãܶȣ¬×¼È·ÐÔÒ»Æð×öµÄ£¬ÅäÈý·ÝÑùÆ·£¬¸ßŨ¶È²âÈý´Î£¬µÍŨ¶È²âÈý´Î£¬ÖÐŨ¶È²âÁù´Î¡£
²â¸ßÖеͻØÊÕÂÊ£¬È¡¾ùÖµ£¬Îª×¼È·¶È¡£
È¡ÖÐŨ¶ÈRSD¾ùÖµ£¬Îª¾«ÃܶÈ
2Â¥2008-09-05 09:51:30
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

penn007

½ð³æ (СÓÐÃûÆø)

¡ï
karl2100(½ð±Ò+1,VIP+0):¶àлÌṩ£¡
³ýÁËÂ¥Éϵģ¬ ÎÒÏë²¹³äһЩÄÚÈÝ£¬ÒòΪÎÒÃÇ»¹Ó¦¸Ã¿¼ÂÇICHµÄÏà¹ØÖ¸ÄÏ£¨ÍêÕûµÄ¼û¸½¼þ2£¬From: http://www.emea.europa.eu/pdfs/human/ich/038195en.pdf£©£¬ÒòΪFDAµÄÖ¸ÄÏ£¨ÉÔÍêÕûÎļþµÄ¼û¸½¼þ1£¬ ³ö´¦http://www.fda.gov/CDER/GUIDANCE/cmc3.pdf£©²¢²»Ïêϸ¡£

FDAµÄÖ¸ÄÏ£¨¼û¸½¼þ1£©¸ø³öÁ˹ØÓÚRECOVERYµÄÒÔÏÂÄÚÈÝ£º
F.    Recovery

           Recovery is expressed as the amount/weight of the compound of interest
           analyzed as a percentage to the theoretical amount present in the
           medium.  

           Full recovery should be obtained for the compound(s) of interest.  During
           the sample preparation procedure, the compound of interest is recovered
           from excipients in the formulation matrix ranging from a simple aqueous
           solution to complex cream formulation, and from potential adhesion to
           container/closure components, e.g., glass vial, metered valve.  In
           general, a simpler sample preparation procedure will result in a lower
           variation of recovery.  Data collection for recovery are discussed in
           section IV.A under Accuracy.

IV.    PARAMETERS FOR VALIDATION OF HPL CHROMATOGRAPHIC
       METHODS FOR DRUG SUBSTANCE AND DRUG PRODUCT

Though many types of HPL chromatographic techniques are available, the most
commonly submitted method, the reversed-phase HPLC with UV detection, is selected
to illustrate the parameters for validation.  The criteria for the validation of this
technique can be extrapolated to other detection methods and chromatographic
techniques.  For acceptance, release or stability testing, accuracy should be optimized
since the need to show deviation from the actual or true value is of the greatest
concern.

       A.     Accuracy

              Accuracy is the measure of how close the experimental value is to the
              true value.
     Accuracy studies for drug substance and drug product are recommended
      to be performed at the 80, 100 and 120% levels of label claim as stated in
      the Guideline for Submitting Samples and Analytical Data for Methods
      Validation.   

      For the drug product, this is performed frequently by the addition of
      known amounts of drug by weight or volume (dissolved in diluent) to the
      placebo formulation working in the linear range of detection of the
      analyte.  This would be a true recovery for liquid formulations.  For
      formulations such as tablet, suppository, transdermal patch, this could
      mean evaluating potential interaction of the active drug with the
      excipients in the diluent.  From a practical standpoint, it is difficult to
      manufacture a single unit with known amount of active drug to evaluate
      recovery.  This test evaluates the specificity of the method in the
      presence of the excipients under the chromatographic conditions used for
      the analysis of the drug product.  It will pick up recovery problems that
      could be encountered during the sample preparation and the
      chromatographic procedures.  However, it does not count the effect of the
      manufacturing process.  

      At each recommended level studied, replicate samples are evaluated.
      The RSD of the replicates will provide the analysis variation or how
      precise the test method is.  The mean of the replicates, expressed as %
      label claim, indicates how accurate the test method is.

      Recommendations:

      Recovery data, at least in triplicate, at each level (80, 100 and 120% of
      label claim) is recommended.  The mean is an estimate of accuracy and
      the RSD is an estimate of sample analysis precision.

µ«ÊÇICHµÄÏà¹ØÖ¸ÄÏ£¨ÍêÕûµÄÎļþ¼û¸½¼þ2£©¸ø³öÁ˸üΪÏêϸµÄÖ¸µ¼Ô­Ôò£¬ Çë×¢Òâ²â¶¨CUʱ£¬
Ó¦¸Ã¿¼ÂÇ70£¥£¬ 100£¥£¬130£¥·¶Î§£»²â¶¨Èܳö¶È»òÔÓÖÊʱµÄ¹æ¶¨ÓÖ²»Ò»ÑùÁË¡£

3. RANGE
The specified range is normally derived from linearity studies and depends on the intended
application of the procedure. It is established by confirming that the analytical procedure
provides an acceptable degree of linearity, accuracy and precision when applied to samples
containing amounts of analyte within or at the extremes of the specified range of the
analytical procedure.

The following minimum specified ranges should be considered:

• for the assay of an active substance or a finished product: normally from 80 to 120
percent of the test concentration;

• for content uniformity, covering a minimum of 70 to 130 percent of the test
concentration, unless a wider more appropriate range, based on the nature of the
dosage form (e.g., metered dose inhalers), is justified;

• for dissolution testing: +/-20 % over the specified range; e.g., if the specifications for a
controlled released product cover a region from 20%, after 1 hour, up to 90%, after 24
hours, the validated range would be 0-110% of the label claim.

• for the determination of an impurity: from the reporting level of an impurity £¨Please refer:
chapters Reporting Impurity Content of Batches of the corresponding
ICH-Guidelines: Impurities in New Drug Substances and Impurities in New Drug Products£©
to 120% of the specification; for impurities known to be unusually potent or to produce toxic or
unexpected pharmacological effects, the detection/ quantitation limit should be
commensurate with the level at which the impurities must be controlled.
Note: for validation of impurity test procedures carried out during development, it may
be necessary to consider the range around a suggested (probable) limit;
1

• if assay and purity are performed together as one test and only a 100% standard is
used, linearity should cover the range from the reporting level of the impurities to
120% of the assay specification.
4Â¥2008-09-13 12:37:49
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

penn007

½ð³æ (СÓÐÃûÆø)

¡ï
karl2100(½ð±Ò+1,VIP+0):¶àлָ½Ì£¡
¶ÔÓÚÖÆ¼ÁÒ»°ãÒÔ»ØÊÕÂÊÊÔÑéÀ´½øÐÐÑéÖ¤¡£ÊÔÑéÉè¼ÆÐ迼ÂÇÔڹ涨·¶Î§ÄÚ£¬ÖƱ¸3¸ö²»Í¬Å¨¶ÈµÄÊÔÑù£¬¸÷²â¶¨3´Î£¬¼´²â¶¨9´Î£¬±¨¸æÒÑÖª¼ÓÈëÁ¿µÄ»ØÊÕÂÊ£¨£¥£©»ò²â¶¨½á¹ûƽ¾ùÖµÓëÕæÊµÖµÖ®²î¼°Æä¿ÉÐÅÏÞ¡£

[ Last edited by penn007 on 2008-9-14 at 03:25 ]
5Â¥2008-09-13 14:33:44
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 2026Ä껪ÄÏʦ·¶´óѧ»¶Ó­»¯Ñ§£¬»¯¹¤£¬ÉúÎÉúÒ½¹¤µÈרҵÓÅÐãѧ×Ó¼ÓÈ룡 +3 llss0711 2026-03-28 6/300 2026-03-29 10:26 by llss0711
[¿¼ÑÐ] ±¾¿ÆÐÂÄÜÔ´¿ÆÑ§Ó빤³Ì£¬Ò»Ö¾Ô¸»ªÀíÄܶ¯285Çóµ÷¼Á +7 AZMK 2026-03-28 11/550 2026-03-28 21:01 by xxxsssccc
[¿¼ÑÐ] 343Çóµ÷¼Á +5 °®î¿°í 2026-03-28 5/250 2026-03-28 20:53 by ÌÆãå¶ù
[¿¼ÑÐ] ѹ¹ú¼ÒÒ»ÇøÏߣ¬Çóµ¼Ê¦ÊÕÁô£¬Óж÷±ØÐ»£¡ +7 ÃÔÈ˵Ĺþ¹þ 2026-03-28 7/350 2026-03-28 16:47 by ´ß»¯´ó°×
[¿¼ÑÐ] 085600£¬²ÄÁÏÓ뻯¹¤321·ÖÇóµ÷¼Á +9 ´ó²öС×Ó 2026-03-28 9/450 2026-03-28 14:56 by ÉñÂí¶¼²»¶®
[¿¼ÑÐ] 346Çóµ÷¼Á Ò»Ö¾Ô¸070303Óлú»¯Ñ§ +3 Âܲ·ìÀÇà²Ë 2026-03-28 3/150 2026-03-28 14:11 by ÌÆãå¶ù
[¿¼ÑÐ] 0703»¯Ñ§Çóµ÷¼Á +9 ÄÌÓͲÝÝ®. 2026-03-22 10/500 2026-03-28 13:30 by ÌÆãå¶ù
[¿¼ÑÐ] µ÷¼Á +3 ºÃºÃ¶ÁÊé¡£ 2026-03-28 3/150 2026-03-28 12:04 by Íõ±£½Ü33
[¿¼ÑÐ] 292Çóµ÷¼Á +14 ¶ì¶ì¶ì¶î¶î¶î¶î¶ 2026-03-25 15/750 2026-03-28 08:45 by WYUMater
[¿¼ÑÐ] 291Çóµ÷¼Á +6 HanBeiNingZC 2026-03-24 6/300 2026-03-28 07:55 by baoball
[¿¼ÑÐ] 308Çóµ÷¼Á +7 īīĮ 2026-03-27 7/350 2026-03-28 07:43 by ÈÈÇéɳĮ
[¿¼ÑÐ] 272Çóµ÷¼Á +7 ½Å»¬µÄÊØ·¨¹«Ãñ 2026-03-27 7/350 2026-03-27 17:23 by laoshidan
[¿¼ÑÐ] 308Çóµ÷¼Á +7 īīĮ 2026-03-25 7/350 2026-03-27 14:47 by ¿ñìÅÂóµ±µ±
[¿¼ÑÐ] 316Çóµ÷¼Á +5 Pigcasso 2026-03-24 5/250 2026-03-27 12:10 by zhshch
[¿¼ÑÐ] 336²ÄÁÏÇóµ÷¼Á +7 ³ÂäÞÓ¨ 2026-03-26 9/450 2026-03-27 00:20 by wxiongid
[¿¼ÑÐ] 302Çóµ÷¼Á +4 ½õÒÂÎÀÌÙ½· 2026-03-25 4/200 2026-03-25 16:29 by ¹¦·ò·è¿ñ
[¿¼ÑÐ] ¡¾2026¿¼Ñе÷¼Á¡¿ÖÆÒ©¹¤³Ì 284·Ö ÇóÏà¹Ø×¨Òµµ÷¼ÁÃû¶î +4 Ô¬Û¼Û¼ 2026-03-25 8/400 2026-03-25 14:32 by lbsjt
[¿¼ÑÐ] Çóµ÷¼Á +3 ÀîÀî²»·þÊä 2026-03-25 3/150 2026-03-25 13:03 by cmz0325
[¿¼ÑÐ] 0854µç×ÓÐÅÏ¢Çóµ÷¼Á 324 +4 Promise-jyl 2026-03-23 4/200 2026-03-25 11:36 by Sugarlight
[¿¼ÑÐ] Ò»Ö¾Ô¸¼ª´ó»¯Ñ§322Çóµ÷¼Á +4 17501029541 2026-03-23 6/300 2026-03-24 10:21 by ´÷Χ²±µÄСÎÃ×Ó
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û